)

Sareum Holdings (SAR) investor relations material
Sareum Holdings H1 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Executive summary
Completed Phase 1 trial for SDC-1801, showing strong safety, pharmacokinetics, and biomarker effects for once-daily dosing in autoimmune diseases, especially psoriasis; no serious adverse events.
Regained control and increased economic interest in SRA737 to 63.5% after license return, enabling new development and licensing opportunities.
Strengthened patent portfolio for SDC-1801 in the US, China, and Japan, enhancing competitive position.
Cash position strengthened to over £4 million at period end, with an additional £1.07 million raised post-period.
Operating expenses and loss after tax significantly reduced year-over-year due to lower clinical trial costs.
Financial highlights
Cash at 31 December 2024 was £4.1 million, up from £1.5 million at 30 June 2024 and £0.4 million at 31 December 2023.
Loss after tax for the six months to 31 December 2024 was just over £1.2 million, improved from £1.8 million (or restated £1.7 million) loss for the same period in 2023.
Revenue for the six months ended 31 December 2024 was £22,000; operating expenses were £1.3 million, down from £2.5 million in the prior year.
Net assets increased to £4.3 million as of 31 December 2024, compared to £1.2 million at 31 December 2023.
Received approximately £1.3 million in investment and R&D tax credit post-period.
Outlook and guidance
SDC-1801 aims for Phase 2 readiness by year-end, with long-term toxicology studies scheduled to complete in Q4 2025.
SDC-1802 preclinical studies are being accelerated, with manufacturing underway and target cancer selection planned.
SRA737 program under review for further commercialization and development, with potential clinical trials and active licensing discussions.
Dual strategy for SDC-1801: preparing for Phase 2 trial while exploring licensing opportunities.
Continued rigorous capital allocation and readiness to respond to new opportunities in kinase inhibitor therapeutics.
Next Sareum Holdings earnings date

Next Sareum Holdings earnings date

The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
)
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage